“…Further evidence for a pro-survival effect of HIF-1a is provided by the delayed apoptosis of human neutrophils observed when HIF is stabilised, either by loss-of-function mutations in von Hippel Lindau (vHL) protein (which targets HIF-1a for degradation) [42], by exposure of healthy volunteers to acute hypoxia [43], or by pharmacologic or genetic manipulation of HIF-1a in zebrafish [44]. Similarly, intermittent hypoxia delayed apoptosis of TNF-a-treated human neutrophils [45], and neutrophils isolated from patients with obstructive sleep apnoea, which is characterised by intermittent hypoxia/reoxygenation, exhibited delayed apoptosis and increased expression of the adhesion molecule CD15 [46]. Hypoxia increases b 2 integrin protein expression, which is again mediated by HIF-1 [47], and may contribute to the hypoxic survival effect; b 2 integrin clustering or activation with endothelial ligands, such as ICAM-1, delays apoptosis through AKT and MAPK-ERK signalling, although b 2 integrin activation in the presence of death-inducing agonists, such as TNF-a, can also accelerate apoptosis.…”